IMODIUM COMPLETE CHEWABLE TABLETS TABLET (CHEWABLE)

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

متاح من:

MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC

ATC رمز:

A07DA53

INN (الاسم الدولي):

LOPERAMIDE, COMBINATIONS

جرعة:

2MG; 125MG

الشكل الصيدلاني:

TABLET (CHEWABLE)

تركيب:

LOPERAMIDE HYDROCHLORIDE 2MG; SIMETHICONE 125MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

5/10/20

نوع الوصفة الطبية :

OTC

المجال العلاجي:

ANTIDIARRHEA AGENTS

ملخص المنتج:

Active ingredient group (AIG) number: 0231812001; AHFS:

الوضع إذن:

CANCELLED POST MARKET

تاريخ الترخيص:

2014-05-21

خصائص المنتج

_ _
_ IMODIUM_
_®_
_ Complete _
_Page 1 of 22_
PRODUCT MONOGRAPH
IMODIUM
®
Complete
Loperamide Hydrochloride, 2 mg/ Simethicone, 125 mg
Oral antidiarrheal/antiflatulent agent
McNeil Consumer Healthcare,
Division of Johnson & Johnson Inc.
88 McNabb St.
Markham, Ontario
L3R 5L2
Date of Revision:
May 22, 2019
Submission Control No: 225986
_ _
_ IMODIUM_
_®_
_ Complete _
_Page 2 of 22_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
5
DRUG INTERACTIONS
...................................................................................................
8
DOSAGE AND ADMINISTRATION
...............................................................................
8
OVERDOSAGE
..................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 10
STORAGE AND STABILITY
.........................................................................................
11
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 11
PART II: SCIENTIFIC INFORMATION
..............................................................................
12
PHARMACEUTICAL INFORMATION
.........................................................................
12
CLINICAL TRIALS
...........................................................................................